CoChat

Adaptive Mitochondrial Reprogramming and Resistance to PI3K Therapy

Open access
Ghosh, Jagadish C., Siegelin, Markus D., Vaira, Valentina, Faversani, Alice, Tavecchio, Michele, Chae, Young Chan, Lisanti, Sofia, Rampini, Paolo, Giroda, Massimo, Caino, M. Cecilia, Seo, Jae Ho, Kossenkov, Andrew V., Michalek, Ryan D., Schultz, David C., Bosari, Silvano, Languino, Lucia R., Altieri, Dario C. · 2015 · JNCI: Journal of the National Cancer Institute
Cited by 108

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Small molecule inhibitors of phosphatidylinositol-3 kinase (PI3K) have been developed as molecular therapy for cancer, but their efficacy in the clinic is modest, hampered by resistance mechanisms. METHODS: We studied the effect of PI3K therapy in patient-derived tumor organotypic cultures (from five patient samples), three glioblastoma (GBM) tumor cell lines, and an intracranial model of glioblastoma in immunocompromised mice (n = 4-5 mice per group). Mechanisms of therapy-induced tumor reprogramming were investigated in a global metabolomics screening, analysis of mitochondrial bioenergetics and cell death, and modulation of protein phosphorylation. A high-throughput drug screening was used to identify novel preclinical combination therapies with PI3K inhibitors, and combination synergy experiments were performed. All statistical methods were two-sided. RESULTS: PI3K therapy induces global metabolic reprogramming in tumors and promotes the recruitment of an active pool of the Ser/Thr kinase, Akt2 to mitochondria. In turn, mitochondrial Akt2 phosphorylates Ser31 in cyclophilin D (CypD), a regulator of organelle functions. Akt2-phosphorylated CypD supports mitochondrial bioenergetics and opposes tumor cell death, conferring resistance to PI3K therapy. The combination of a small-molecule antagonist of CypD protein folding currently in preclinical development, Gamitrinib, plus PI3K inhibitors (PI3Ki) reverses this adaptive response, produces synergistic anticancer activity by inducing mitochondrial apoptosis, and extends animal survival in a GBM model (vehicle: median survival = 28.5 days; Gamitrinib+PI3Ki: median survival = 40 days, P = .003), compared with single-agent treatment (PI3Ki: median survival = 32 days, P = .02; Gamitrinib: median survival = 35 days, P = .008 by two-sided unpaired t test). CONCLUSIONS: Small-molecule PI3K antagonists promote drug resistance by repurposing mitochondrial functions in bioenergetics and cell survival. Novel combination therapies that target mitochondrial adaptation can dramatically improve on the efficacy of PI3K therapy in the clinic.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jnci/dju502

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 108

Metadata

Authors
Ghosh, J. C., Siegelin, M. D., Vaira, V., Faversani, A., Tavecchio, M., Chae, Y. C., Lisanti, S., Rampini, P., Giroda, M., Caino, M. C., Seo, J. H., Kossenkov, A. V., Michalek, R. D., Schultz, D. C., Bosari, S., Languino, L. R., & Altieri, D. C.
Venue
JNCI: Journal of the National Cancer Institute
Published
2015-02-03
Volume
107
Issue
3
ISSN
  • 0027-8874 (ISSN-L)
  • 1460-2105
OpenAlex
W2140163306
Cited by
108
References
17
FWCI
5.66
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Adaptive Mitochondrial Reprogramming and Resistance to PI3K Therapy. https://app.cochat.ai/papers/10.1093/jnci/dju502
The paper
Ghosh, J. C., Siegelin, M. D., Vaira, V., Faversani, A., Tavecchio, M., Chae, Y. C., Lisanti, S., Rampini, P., Giroda, M., Caino, M. C., Seo, J. H., Kossenkov, A. V., Michalek, R. D., Schultz, D. C., Bosari, S., Languino, L. R., & Altieri, D. C. (2015). Adaptive Mitochondrial Reprogramming and Resistance to PI3K Therapy. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/dju502

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.